1. KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline
Holly J. Kramer, Raymond R. Townsend, Karen Griffin, Joseph T. Flynn, Daniel E. Weiner, Michael V. Rocco, Michael J. Choi, Matthew R. Weir, Tara I. Chang, Rajiv Agarwal, Srinivasan Beddhu 
American Journal of Kidney Diseases 
Volume 73, Issue 4, Pages (April 2019)
DOI: /j.ajkd
Copyright © 2019 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Hazard ratios of kidney outcomes by use of non-thiazide blood pressure–lowering medications versus thiazide diuretic (THZ) medications. Abbreviations: ACE, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers. Data obtained from Reboussin et al.79
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2019 National Kidney Foundation, Inc. Terms and Conditions

3. Figure 2
Average number of blood pressure (BP) medications needed to achieve a BP goal in clinical trials. Abbreviations: AASK, African American Study of Kidney Disease and Hypertension93; ACCORD, Action to Control Cardiovascular Disease in Diabetes77; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; CKD, chronic kidney disease; IDNT, Irbesartan Diabetic Nephropathy Trial132; MDRD, Modification of Diet in Renal Disease94; RENAAL, Reduction of Endpoints in NIDDM With the Angiotensin II Antagonist Losartan133,134 SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial3; UKPKDS, United Kingdom Prospective Kidney Disease Study.134
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2019 National Kidney Foundation, Inc. Terms and Conditions